Literature DB >> 18374504

Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer.

Tomo Suga1, Mayumi Iwakawa, Hiroshi Tsuji, Hitoshi Ishikawa, Eisei Oda, Shuhei Noda, Yoshimi Otsuka, Atsuko Ishikawa, Ken-Ichi Ishikawa, Jun Shimazaki, Jun-Etsu Mizoe, Hirohiko Tsujii, Takashi Imai.   

Abstract

PURPOSE: To investigate the genetic risk of late urinary morbidity after carbon ion radiotherapy in prostate cancer patients. METHODS AND MATERIALS: A total of 197 prostate cancer patients who had undergone carbon ion radiotherapy were evaluated for urinary morbidity. The distribution of patients with dysuria was as follows: Grade 0, 165; Grade 1, 28; and Grade 2, 4 patients. The patients were divided (2:1) consecutively into the training and test sets and then categorized into control (Grade 0) and case (Grade 1 or greater) groups. First, 450 single nucleotide polymorphisms (SNPs) in 118 candidate genes were genotyped in the training set. The associations between the SNP genotypes and urinary morbidity were assessed using Fisher's exact test. Then, various combinations of the markers were tested for their ability to maximize the area under the receiver operating characteristics (AUC-ROC) curve analysis results. Finally, the test set was validated for the selected markers.
RESULTS: When the SNP markers in the SART1, ID3, EPDR1, PAH, and XRCC6 genes in the training set were subjected to AUC-ROC curve analysis, the AUC-ROC curve reached a maximum of 0.86. The AUC-ROC curve of these markers in the test set was 0.77. The SNPs in these five genes were defined as "risk genotypes." Approximately 90% of patients in the case group (Grade 1 or greater) had three or more risk genotypes.
CONCLUSIONS: Our results have shown that patients with late urinary morbidity after carbon ion radiotherapy can be stratified according to the total number of risk genotypes they harbor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374504     DOI: 10.1016/j.ijrobp.2008.01.029

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma.

Authors:  Isabella Wai Yin Cheuk; Shea Ping Yip; Dora Lai Wan Kwong; Vincent Wing Cheung Wu
Journal:  Mol Clin Oncol       Date:  2014-04-14

2.  Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.

Authors:  Barry S Rosenstein
Journal:  Pharmacogenomics       Date:  2011-02       Impact factor: 2.533

Review 3.  Individual response of humans to ionising radiation: governing factors and importance for radiological protection.

Authors:  K E Applegate; W Rühm; A Wojcik; M Bourguignon; A Brenner; K Hamasaki; T Imai; M Imaizumi; T Imaoka; S Kakinuma; T Kamada; N Nishimura; N Okonogi; K Ozasa; C E Rübe; A Sadakane; R Sakata; Y Shimada; K Yoshida; S Bouffler
Journal:  Radiat Environ Biophys       Date:  2020-03-07       Impact factor: 1.925

4.  Genetics and genomics of radiotherapy toxicity: towards prediction.

Authors:  Catharine M West; Gillian C Barnett
Journal:  Genome Med       Date:  2011-08-23       Impact factor: 11.117

5.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  No association between TGFB1 polymorphisms and late radiotherapy toxicity: a meta-analysis.

Authors:  Mei-Ling Zhu; MengYun Wang; Ting-Yan Shi; Qiao-Xin Li; Pan Xi; Kai-Qin Xia; Leizhen Zheng; Qing-Yi Wei
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

Review 7.  The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.

Authors:  Thomas Van den Broeck; Steven Joniau; Liesbeth Clinckemalie; Christine Helsen; Stefan Prekovic; Lien Spans; Lorenzo Tosco; Hendrik Van Poppel; Frank Claessens
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

8.  EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness.

Authors:  F Gimeno-Valiente; Á L Riffo-Campos; G Ayala; N Tarazona; V Gambardella; F M Rodríguez; M Huerta; C Martínez-Ciarpaglini; J Montón-Bueno; S Roselló; D Roda; A Cervantes; L Franco; G López-Rodas; J Castillo
Journal:  Sci Rep       Date:  2020-02-28       Impact factor: 4.379

9.  EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker.

Authors:  Ruochan Chen; Yiya Zhang
Journal:  J Cell Mol Med       Date:  2020-09-15       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.